Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss
Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with facial alterations of variable magnitude. 2-4 Patients may experience facial changes such as dry, dull or sagging skin, a gaunt or hollowed-out facial appearance, or other unwelcome alterations to facial structure and balance. 3,4 As the pure-play dermatology category leader, Galderma is spearheading efforts to identify and address the most predominant aesthetic concerns of patients along their weight loss journey.
"At Galderma, we are leading the charge in redefining aesthetic care for patients impacted by medication-driven weight loss. Our commitment is clear: to empower individuals to reclaim their confidence through cutting-edge, data-driven innovation and strategic collaboration with the world's foremost experts, and these latest study results reinforce this mission."
FLEMMING ØRNSKOV, M.D., MPH
CHIEF EXECUTIVE OFFICER
GALDERMA
In the phase IV clinical study conducted in the U.S., Galderma investigated the aesthetic outcomes and appearance, and patient satisfaction of Restylane Lyft or Contour in combination with Sculptra for cheek or jawline augmentation and correction of contour deficiencies in patients experiencing facial volume loss associated with medication-driven weight loss. 1 The trial used the SHAPE Up Holistic Individualized Treatment (HIT™) – an individualized treatment approach which enables injectors to leverage their expertise with Galderma's Sculptra and its Restylane portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction.
Patients were treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8. 1
Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months. In the extension study, follow-up visits took place at Weeks 32 and 44 for those who received the third Sculptra treatment and at Weeks 28 and 40 for those who did not, corresponding to nine months after their first Sculptra treatment. 1
Results at nine months demonstrated that the combination of Sculptra and Restylane Lyft or Contour effectively improved the aesthetic appearance of patients experiencing facial volume loss associated with medication-driven weight loss, further supporting the benefits of the SHAPE Up HIT: 1
The combined Sculptra and Restylane Lyft or Contour regimen demonstrated skin quality improvements, with Restylane improving skin hydration and Sculptra significantly improving skin radiance through to Month 9 1
Subject satisfaction – which was reported by the majority of patients as early as Week 4 – was maintained through to Month 9: 1
85.7% of patients said their face looked less gaunt/sunken 1
88.6% said they 'loved' how the treatment maintained their facial structure 1
88.6% of patients said they 'loved' the regenerative effects of Sculptra treatment 1
88.6% felt they looked better than before the injection regimen 1
91.4% said they would recommend the injection regimen to others after weight loss and to those with loose, sagging facial skin 1
Safety was in line with previous pivotal trial data for Sculptra, Restylane Lyft and Contour, with no treatment-related adverse events reports. 1
"The improvements we observed with Sculptra and Restylane at nine months are hugely encouraging and represent a meaningful step forward in addressing the most predominant aesthetic concerns of patients along their weight loss journey. It was exciting to see the glow we've clinically observed in the past with Sculptra now validated through innovative bioinstrumentation tools in this study. For physicians and patients who are navigating the visible effects of medication-driven weight loss, this study delivers real, evidence-based solutions that can make a tangible difference to how individuals look and feel."
Z. PAUL LORENC, M.D.
CLINICAL TRIAL INVESTIGATOR
NEW YORK, UNITED STATES
"These results really reinforce the role of aesthetic treatments, like Sculptra and Restylane, in supporting patients through their weight loss transformations, showing they can deliver visible improvements in skin quality while also significantly enhancing patient satisfaction and emotional wellbeing. The findings empower clinicians with data-backed tools to holistically address the nuanced aesthetic needs that arise with medication-driven weight loss, marking a pivotal moment where science meets patient-centered care."
MICHAEL SOMENEK, M.D.
CLINICAL TRIAL INVESTIGATOR
WASHINGTON DC, UNITED STATES
Galderma is spearheading multiple additional initiatives to identify and address the most predominant aesthetic concerns of patients who have experienced medication-driven weight loss through data-driven, innovative approaches in close collaboration with leading healthcare practitioners, as outlined in the company's recent report. 5 Galderma has supported pioneering research in the field, including the first recently published international consensus-based guidelines that provide a practical framework for practitioners to address the aesthetic needs of medication-driven weight loss patients, as well as research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient journey. 6
* Restylane Contour is known as Restylane ® Volyme™ in countries outside of the U.S.
About the study
This phase IV trial was a multi-center, open-label study to evaluate the synergistic effects of Restylane Lyft or Contour in combination with Sculptra for cheek augmentation and correction of contour deficiencies, in patients experiencing facial volume loss following treatment with one of four brands of glucagon-like peptide-1 (GLP-1) receptor agonists. 1 Conducted in the U.S., the trial took place across two sites, and used the SHAPE Up Holistic Individualized Treatment (HIT) as a treatment methodology, with patients treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8. 1
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References
Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label study to evaluate the synergistic effects of biostimulator and dermal fillers for cheek augmentation and correction of contour deficiencies: Nine-month topline results.
Mansour MR, et al. The rise of 'Ozempic Face': Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. JPRAS. 2024;96:225-227. doi: 10.1016/j.bjps.2024.07.051
Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. JPRAS. 2023;81:97-98. doi: 10.1016/j.bjps.2023.04.057
Humphrey CD and Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721. doi: 10.1055/a-2148-6321
Galderma. Balancing The Scales: Advancing Aesthetics In The Era Of Medication-driven Weight Loss Transformations. July 2025. Available online
Nikolis A, et al. Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study. JCD https://doi.org/10.1111/jocd.70094
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Overture Life Signs Agreement With Memorial Hospital Istanbul for World's First Commercial Automated IVF Technology
Overture's ICSI.A technology enabled first babies born from automated fertilization in 2023 Platform will now support one of the highest volume IVF clinics in the world at Memorial Hospital Istanbul, expected to assist in over 6,000 IVF cycles per year – and growing PALO ALTO, Calif., July 17, 2025--(BUSINESS WIRE)--Overture Life, the innovator modernizing IVF to optimize reproductive freedom, announced the first commercial sale of an automated in vitro fertilization (IVF) platform to Memorial Hospital Istanbul, home to one of Europe's leading fertility centers. Overture's ICSI.A platform automates a complex fertilization process known as piezo-assisted intracytoplasmic sperm injection (piezo-ICSI), which uses electric pulses to fertilize eggs more gently than manual injection methods. Overture's ICSI.A enabled the first live births resulting from an automated fertilization1, in 2023. Memorial Hospital Istanbul will use the devices to simplify thousands of IVF cycles per year, with the additional efficiency expected to grow its capacity even further. The growth of automated IVF technologies is critical for patients dealing with infertility, who often struggle to access IVF, whether due to cost, capacity or the toll that multiple IVF cycles can take, emotionally and physically. Overture is dedicated to making IVF easier to perform and less expensive, enabling every embryologist and IVF center to provide premium quality regardless of location, size, or clientele. The company is now poised for rapid commercial growth, backed by peer-reviewed science and rigorous regulatory oversight. Published data suggests piezo-ICSI leads to better quality eggs and blastocytes2, resulting in higher fertility rates. In particular, ICSI.A has demonstrated high proficiency even when operated by inexperienced personnel3 – an important factor given the years of training and practice typically needed to optimize this skillset among embryologists. "Memorial Hospitals have some of the best embryologists in the world, making us a magnet in the region for those struggling with infertility. Despite our proficiency, demand continues to rise, and we are committed to maintaining the best quality as we expand capacity," said Prof Dr Semra Kahraman of the In Vitro Fertilization (IVF) Andrology and Genetics Center at Memorial Hospital Istanbul. "Automated platforms like Overture Life's ICSI.A are game-changing technologies, and will be key for helping us scale effectively." "This exciting commercial commitment from Memorial Hospital, known worldwide for its impressive IVF clinic, is the latest milestone to cement Overture's leadership in the IVF automation space," said Hans Gangeskar, CEO of Overture Life. "This year has already seen a sizable strategic fundraise, regulatory clearance and commercialization for our DaVitri platform for fertility preservation, and CLIA licensure for our AI-powered, non-invasive metabolomic test for embryo selection, m|z. We look forward to rolling out ICSI.A in Turkey and changing the lives of more families eager to take control of their own destiny." Memorial Hospital Istanbul is expected to install Overture Life's ICSI.A robots by the end of this year. About Overture Life Overture Life integrates engineering, reproductive medicine, and regulatory-grade validation to modernize embryology lab procedures, particularly fertility preservation and embryo handling, in ways that lower repeated cycles, increase throughput, and reduce the overall cost of IVF. With R&D in Spain and active U.S. operations, including a CLIA-licensed laboratory for non-invasive embryo selection, Overture unites robotics, analytics, and clinical rigor to deliver tools that clinics and patients can trust. The company's DaVitri platform aims to boost reliability and consistency in IVF, giving women and families worldwide more control over their fertility timelines. Overture's backers include Overwater Ventures, GV (formerly Google Ventures), Khosla Ventures, Octopus Ventures and others committed to advancing the future of fertility. 1 The first babies conceived with a sperm-injecting robot have been born [Internet]. MIT Technology Review. Available from: 2 Furuhashi K, Saeki Y, Enatsu N, Iwasaki T, Ito K, Mizusawa Y, Matsumoto Y, Kokeguchi S, Shiotani M. Piezo-assisted ICSI improves fertilization and blastocyst development rates compared with conventional ICSI in women aged more than 35 years. Reprod Med Biol. 2019 Aug 24;18(4):357-361. doi: 10.1002/rmb2.12290. PMID: 31607795; PMCID: PMC6780025.3 Costa-Borges N, Munné S, Albó E, Mas S, Castelló C, Giralt G, Lu Z, Chau C, Acacio M, Mestres E, Matia Q, Marquès L, Rius M, Márquez C, Vanrell I, Pujol A, Mataró D, Seth-Smith M, Mollinedo L, Calderón G, Zhang J. First babies conceived with Automated Intracytoplasmic Sperm Injection. Reprod Biomed Online. 2023 Sep;47(3):103237. doi: 10.1016/ Epub 2023 May 25. PMID: 37400320. View source version on Contacts Media Contact overture@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
New Study in JAMA Network Open Shows Current Approaches to Assessing Preeclampsia Risk Are Failing the Majority of Pregnant Moms
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- A new study sponsored by Mirvie, which is the first to evaluate U.S. Preventive Services Task Force (USPSTF) guidelines for preeclampsia risk and aspirin prescription in a single, nationally representative, prospective population, found while high-risk factors had sufficient value in estimating risk, there's limited value for the moderate risk category - leading to nonspecific recommendations for aspirin use, a recognized prevention tool. This cohort study of 5684 participants, culled from the multi-center Miracle of Life prospective study, found the guidelines identified nearly 89% of pregnancies at increased risk of preeclampsia. 70.3% were in the moderate risk category, defined by maternal characteristics and broad demographics including age, body mass index, and race, while 18.5% were in the high risk category, which includes patients with conditions like chronic hypertension or prior history of preeclampsia. The study findings suggest that the murkiness of moderate risk factors may influence clinicians' decisions regarding daily aspirin recommendations. While 82% of women with a high risk factor were recommended daily aspirin, only 37% of those with one or more moderate risk factors were given this recommendation. USPSTF, American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) all endorse guidance to consider or recommend starting aspirin between 12 to 28 weeks' gestation for pregnancies with moderate risk factors. 'Identifying 9 out of 10 women as at risk is not helping and overburdens care teams and pregnant patients, too,' said Dr. Thomas McElrath, vice president of clinical development at Mirvie and a practicing maternal-fetal medicine physician at Mass General Brigham, as well as lead author of the study. 'Physicians may be reluctant to prescribe aspirin when the majority of their patients fall into the moderate risk category. This is compounded by less than 25% compliance with aspirin use by patients in the moderate risk category.' Most pregnant women in the study (70.3%) fell into the moderate risk category using the USPSTF guidelines, but having one or more moderate risk factors and no high-risk factors were not predictive of preeclampsia risk. Among individuals with 2 or more moderate risk factors but without any high risk factor, nulliparity was associated with modestly increased risk of preeclampsia (RR, 1.48; 95% CI, 1.35-1.62; P < .001); there was little or no association with obesity (RR, 1.11; 95% CI, 1.01-1.22; P = .048), Black race (RR, 0.95; 95% CI, 0.80-1.14; P = .63), and advanced maternal age (RR, 0.79; 95% CI, 0.65-0.96; P = .02). 'Rates of preeclampsia in the US have doubled in the past 15 years and continue to rise with no end in sight,' said Kara Boeldt, a preeclampsia survivor and Founder and Executive Director of 'The introduction of the USPSTF guidelines in 2021 didn't do anything to reverse course on the rise of preeclampsia. This important and eye-opening study highlights that we need new approaches that can predict who's truly at risk for preeclampsia, which can be so dangerous for moms and their babies. This is why I am incredibly encouraged and excited by the innovation being led by companies like Mirvie, which can finally offer some pregnant women and their care teams a clear, personalized prediction of their preeclampsia risk with a simple blood test during pregnancy." 'The findings of this important study confirm the need for clear, objective measures of preeclampsia risk prediction, to motivate preventive care,' said Maneesh Jain, CEO and co-founder of Mirvie. 'With innovation like Encompass ™, we can now deliver preventive care to the right patients at the right time and impact rates of preterm birth.' About the Miracle of Life study The Mirvie-sponsored Miracle of Life study examined nearly 11,000 pregnancies across the U.S., including 22,000 cell-free RNA transcripts per patient which resulted in 200 million data points overall, making it the largest study of molecular health in pregnancy of its kind. The landmark research study on pregnancy health, in collaboration with leading experts in obstetrics and maternal-fetal medicine, uncovers how RNA messages present in expectant mothers' blood can predict life-threatening pregnancy complications. One area of study relates to cell-free RNA's prediction of preeclampsia months in advance, a leading cause of pregnancy-related morbidity and mortality. About Mirvie Mirvie is bringing scientifically rigorous and data-driven approaches to solving some of the most pressing clinical problems in women's health, beginning with pregnancy. Serious complications impact one in five pregnancies in the U.S., and Mirvie is committed to creating a world where every pregnancy is as safe and healthy as possible. Founded and led by a team of seasoned entrepreneurs and scientists, the company is based in South San Francisco, California and backed by top-tier investors including Blackrock, Decheng Capital, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield. For more information, visit
Business Wire
3 hours ago
- Business Wire
Boston IVF Expands Access to Advanced Fertility Services in Syracuse with Addition of Dr. Wendy Vitek
SYRACUSE, N.Y.--(BUSINESS WIRE)-- Boston IVF, one of the nation's leading reproductive service providers and a pioneer in IVF research, welcomed Dr. Wendy Vitek, a board-certified reproductive endocrinologist, to its Syracuse, New York fertility center. Triple board certified in Obstetrics and Gynecology (OB/GYN), Reproductive Endocrinology and Infertility (REI), and Obesity Medicine, her arrival underscores Boston IVF's commitment to expanding access to world-class fertility care, including IVF, egg freezing, and fertility preservation, for individuals and couples throughout Syracuse, Rochester, the Finger Lakes, and upstate New York, and reinforces the company's clinical leadership in the region. 'Dr. Vitek has extraordinary clinical skill, a deep sense of compassion, and more than a decade of experience,' said Alan S. Penzias, MD, Northeast Region Medical Director of Boston IVF. 'She is a standout in the field of reproductive medicine and her presence in Syracuse allows us to serve more individuals and couples with high-quality, patient-centered care.' Dr. Vitek also holds a faculty appointment at Upstate Medical Center and is an adjunct professor at the University of Rochester Medical Center. From 2021 to 2025, she served as Program Director of a nationally accredited REI fellowship program, where she mentored the next generation of reproductive medicine specialists, and serves on national advisory boards focused on reproductive health and medical education. She has led clinical trials, including the NatPro study, participated in FDA device research, and published research on frozen embryo transfer (FET) protocols, PCOS, obesity, and infertility. 'I'm honored to join the Boston IVF team and to serve patients in Syracuse and beyond,' said Dr. Wendy Vitek. 'Boston IVF's reputation for clinical excellence, innovation, research, and compassionate care makes this an especially exciting time to come on board. I am delighted to help individuals and couples achieve their dream of building a family—it's the most rewarding work I can imagine.' Dr. Vitek is now accepting new patients in person at Boston IVF's Syracuse fertility center. Schedule a consultation here or call (888) 300-9660. Dr. Vitek earned her medical degree from the University of Rochester School of Medicine and Dentistry, completed her OB/GYN residency at Magee-Womens Hospital of UPMC, and her fellowship in Reproductive Endocrinology and Infertility at Women & Infants Hospital. About Boston IVF Boston IVF is one of the largest and most experienced fertility networks in the United States, with more than 150,000 babies born since 1986. Founded as one of the nation's first private practice IVF centers, the Boston IVF network has grown to include 40 reproductive endocrinologists across nearly 30 centers throughout Massachusetts, Maine, New Hampshire, Rhode Island, New York, Delaware, Idaho, Indiana, North Carolina, Ohio, and Utah. A renowned innovator of reproductive technologies, advanced protocols, and cutting-edge research, Boston IVF has achieved numerous "firsts" in reproductive care. Its scientific and research arm continues to pave the way for breakthroughs in fertility care and its accredited REI Fellowship Program has graduated numerous reproductive endocrinologists as part of its mission to train the next generation of fertility experts. In 2024, Boston IVF joined the global IVI RMA Network, contributing to the network's management of more than 20+ labs and 60 satellites across North America. In 2025, Boston IVF was named one of Castle Connolly's Top 5 Private Practices for Top Doctors in Reproductive Medicine in the Nation, a distinction that reflects the organization's continued leadership in reproductive science, innovation, and compassionate care.
